Plain-English translation of NCT07373964 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether chidamide, combined with three other medications (a type of immunotherapy drug, carboplatin, and etoposide), can help people with advanced small-cell lung cancer live longer without their cancer growing. Small-cell lung cancer is an aggressive type that often spreads quickly. Researchers hope this new combination might work better than current standard treatments.
Advanced small-cell lung cancer is very difficult to treat, and current treatments don't work well enough for many patients. This trial exists to see whether adding a new medication to the standard chemotherapy and immunotherapy approach might improve outcomes and give patients more time before their cancer returns or worsens.
You likely qualify if…
You likely don't qualify if…
You would receive four medications together as your first treatment for advanced lung cancer. For the first 4 months, you would receive chidamide tablets by mouth along with intravenous chemotherapy and immunotherapy. After that initial phase, you would continue taking chidamide by mouth to help maintain the effect. You would have regular visits to your doctor for blood tests, scans, and check-ups to see how well the treatment is working and to watch for any side effects. The trial will follow you until your cancer progresses or you experience side effects that are too difficult to manage.
AI-generated summary from trial data · Aug 1, 2026 · Not medical advice
China